<DOC>
	<DOCNO>NCT02406781</DOCNO>
	<brief_summary>This multicenter study assess efficacy MK 3475 ( Pembrolizumab ) combination metronomic cyclophosphamide patient advance sarcoma .</brief_summary>
	<brief_title>Combination MK3475 Metronomic Cyclophosphamide Patients With Advanced Sarcomas : Multicentre Phase II Trial</brief_title>
	<detailed_description>This phase 2 trial 5 stratum : - Leiomyosarcoma : 33 patient - Undifferentiated sarcoma : 33 patient - Sarcomas others : 33 patient - Osteosarcoma : 33 patient - GIST : 31 patient</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Histology : Leiomyosarcoma , UPS , sarcoma , GIST osteosarcoma , histologically confirmed central review 2 . Advanced non resectable / metastatic disease 3 . Documented progression accord RECIST criterion . Progression last line treatment confirm central review two radiological assessment identical obtain less 6 month interval within 12 month inclusion 4 . For stratum 5 , document disease progression accord RECIST criterion first line imatinib second line sunitinib 5 . Have provide tissue archival tissue sample obtain metastasis locally advanced disease , newly obtain core excisional biopsy tumor lesion 6 . For stratum 1 , 2 3 : four previous line systemic therapy metastatic disease 7 . Age ≥ 18 year 8 . ECOG performance status ≤ 1 9 . Measurable disease accord RECIST v1.1 outside previously irradiated field . At least one site disease must unidimensionally ≥ 10 mm 10 . Life expectancy &gt; 3 month 11 . ≥ 1 previous line ( ) chemotherapy palliative set 12 . No symptomatic central nervous system disease 13 . No chronic use glucocorticoid 14 . Adequate hematological , renal , metabolic hepatic function : 1 . Hemoglobin ≥ 9 g/dl ( patient may receive prior red blood cell transfusion ) ; ANC ≥ 1.5 x 109/l platelet count ≥ 100 x 109/l , lymphocyte count ≥ 1.109 /l 2 . ALT AST ≤ 2.5 x upper limit normality ( ULN ) ( ≤ 5 case liver metastasis ) 3 . Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN subject total bilirubin level ≥ 1.5 x ULN 4 . Albumin ≥ 25g/l 5 . Serum creatinine ≤ 1.5 x ULN OR CrCl ≥ 60 ml/min subject creatinine level ≥ 1.5 x ULN , 6 . Creatine phosphokinase ≤ 2.5 x ULN 7 . INR ≤ 1.5 x ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 8. aPTT ≤ 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 15 . No prior concurrent malignant disease diagnose treat last 2 year except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 16 . At least three week since last chemotherapy , immunotherapy pharmacological treatment and/or radiotherapy 17 . Recovery grade ≤ 1 adverse event previous treatment ( exclude alopecia grade nonpainful peripheral neuropathy grade ≤ 2 ( NCICTCAE , v 4.0 ) 18 . Women childbearing potential must negative serum pregnancy test within 72 hour prior receive first dose study medication . Both woman men must agree use medically acceptable method contraception throughout treatment period four month discontinuation treatment . Acceptable method contraception include intrauterine device , oral contraceptive , subdermal implant double barrier . Subjects childbearing potential surgically sterilize free menses ≥ 1 year 19 . Voluntary sign dated write informed consent prior specific study procedure 20 . Patients French social security compliance Law relate biomedical research ( Article 112111 French Public Health Code ) 1 . Previous treatment MK3475 CP 2 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) 3 . Evidence progressive symptomatic central nervous system ( CNS ) leptomeningeal metastases 4 . Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feed 5 . Participation study involve medical therapeutic intervention last 30 day 6 . Previous enrolment present study 7 . Patient unable follow comply study procedure geographical , familial , social psychological reason 8 . Known hypersensitivity involve study drug formulation component 9 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study 10 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment 11 . History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia , evidence active pneumonitis screen chest CT scan . History radiation pneumonitis radiation field ( fibrosis ) permit 12 . Has know active hepatitis B hepatitis C 13 . Has know history HIV ( HIV1/2 antibody ) , 14 . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Efficacy MK 3475 Metronomic Cyclophosphamide</keyword>
	<keyword>Advanced Sarcomas</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Undifferentiated Sarcoma</keyword>
	<keyword>Other Sarcoma</keyword>
	<keyword>GIST</keyword>
	<keyword>Osteosarcoma</keyword>
</DOC>